Search results
Results from the WOW.Com Content Network
Targeted molecular therapy for neuroblastoma involves treatment aimed at molecular targets that have a unique expression in this form of cancer. Neuroblastoma, the second most common pediatric malignant tumor, often involves treatment through intensive chemotherapy. A number of molecular targets have been identified for the treatment of high ...
The Mayo Clinic Cancer Center is one of the oldest NCI-designated cancer centers in the United States, having first been designated in 1973. [3] The main location of the Mayo Clinic is in Rochester, MN. Campuses in Arizona and Florida opened later and became part of the Mayo Clinic Cancer Center in 2003. [4] [5]
In high-risk disease, chances of long-term survival, however, are less than 40%, despite aggressive treatment. [5] Neuroblastoma is the most common cancer in babies and the third-most common cancer in children after leukemia and brain cancer. [5] About one in every 7,000 children is affected at some time. [2]
Chemotherapy is a treatment that uses a tumor-killing drug to prevent the growth of cancer cells by stopping them from dividing. It is often used after surgery or as the first line of treatment. It is often used after surgery or as the first line of treatment.
The degree of differentiation of neuroblastoma is correlated to the prognosis, with a wide variety of outcomes (from tumor regression to recurrence and mortality). The standard of care is the use of chemotherapy, surgical resection and radiation, although most aggressive neuroblastomas have demonstrated to be resistant to these therapies.
This is an accepted version of this page This is the latest accepted revision, reviewed on 28 January 2025. Neoplasm in the brain Medical condition Brain tumor Other names Intracranial neoplasm, brain tumour, brain cancer Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic resonance imaging Specialty Neurosurgery, neuro-oncology Symptoms Vary depending on the ...
The concept of grading of the tumors of the central nervous system, agreeing for such the regulation of the "progressiveness" of these neoplasias (from benign and localized tumors to malignant and infiltrating tumors), dates back to 1926 and was introduced by P. Bailey and H. Cushing, [1] in the elaboration of what turned out the first systematic classification of gliomas.
Originating from a mouse, the N2a cell line has a neuronal and amoeboid stem cell morphology, allowing it to differentiate in response to environmental factors. The differentiated cells have many properties of neurons, including neurofilaments.